TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ribomic, Inc. ( (JP:4591) ) has provided an update.
RIBOMIC, Inc. announced the sustained efficacy of its drug, umedaptanib pegol, in a long-term administration trial for pediatric patients with achondroplasia. The trial demonstrated that the drug significantly increased the height growth rate of patients, surpassing the current standard treatment, Voxzogo. This development could lead to improved quality of life for individuals with achondroplasia, as the drug targets the disease’s pathogenic mechanism directly. No safety concerns have been reported in the ongoing trials.
More about Ribomic, Inc.
RIBOMIC, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of aptamer therapeutics, a type of nucleic acid medicine. The company utilizes its RiboART system, a core drug discovery platform, to develop drugs for unmet medical needs, including eye diseases and rare childhood diseases such as short stature.
Average Trading Volume: 2,292,784
Technical Sentiment Signal: Buy
Current Market Cap: Yen5.03B
For an in-depth examination of 4591 stock, go to TipRanks’ Overview page.